{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:17:48Z","timestamp":1790072268225,"version":"4.0.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2013,5,27]],"date-time":"2013-05-27T00:00:00Z","timestamp":1369612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,5,27]],"date-time":"2013-05-27T00:00:00Z","timestamp":1369612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1038\/aps.2013.40","type":"journal-article","created":{"date-parts":[[2013,5,27]],"date-time":"2013-05-27T08:58:26Z","timestamp":1369645106000},"page":"930-938","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Synergistic suppression of noscapine and conventional chemotherapeutics on human glioblastoma cell growth"],"prefix":"10.1038","volume":"34","author":[{"given":"Qi","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish C","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keqiang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,27]]},"reference":[{"key":"BFaps201340_CR1","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1073\/pnas.95.4.1601","volume":"95","author":"K Ye","year":"1998","unstructured":"Ye K, Ke Y, Keshava N, Shanks J, Kapp JA, Tekmal RR, et al. Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc Natl Acad Sci U S A 1998; 95: 1601\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"BFaps201340_CR2","first-page":"4109","volume":"62","author":"JW Landen","year":"2002","unstructured":"Landen JW, Lang R, McMahon SJ, Rusan NM, Yvon AM, Adams AW, et al. Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Cancer Res 2002; 62: 4109\u201314.","journal-title":"Cancer Res"},{"key":"BFaps201340_CR3","doi-asserted-by":"publisher","first-page":"17200","DOI":"10.1074\/jbc.M110369200","volume":"277","author":"J Zhou","year":"2002","unstructured":"Zhou J, Panda D, Landen JW, Wilson L, Joshi HC . Minor alteration of microtubule dynamics causes loss of tension across kinetochore pairs and activates the spindle checkpoint. J Biol Chem 2002; 277: 17200\u20138.","journal-title":"J Biol Chem"},{"key":"BFaps201340_CR4","doi-asserted-by":"publisher","first-page":"39777","DOI":"10.1074\/jbc.M203927200","volume":"277","author":"J Zhou","year":"2002","unstructured":"Zhou J, Gupta K, Yao J, Ye K, Panda D, Giannakakou P, et al. Paclitaxel-resistant human ovarian cancer cells undergo c-Jun NH2-terminal kinase-mediated apoptosis in response to noscapine. J Biol Chem 2002; 277: 39777\u201385.","journal-title":"J Biol Chem"},{"key":"BFaps201340_CR5","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1242\/jcs.00029","volume":"115","author":"J Zhou","year":"2002","unstructured":"Zhou J, Yao J, Joshi HC . Attachment and tension in the spindle assembly checkpoint. J Cell Sci 2002; 115: 3547\u201355.","journal-title":"J Cell Sci"},{"key":"BFaps201340_CR6","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1158\/1078-0432.CCR-04-0360","volume":"10","author":"JW Landen","year":"2004","unstructured":"Landen JW, Hau V, Wang M, Davis T, Ciliax B, Wainer BH, et al. Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth. Clin Cancer Res 2004; 10: 5187\u2013201.","journal-title":"Clin Cancer Res"},{"key":"BFaps201340_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s002620000109","volume":"49","author":"Y Ke","year":"2000","unstructured":"Ke Y, Ye K, Grossniklaus HE, Archer DR, Joshi HC, Kapp JA . Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses. Cancer Immunol Immunother 2000; 49: 217\u201325.","journal-title":"Cancer Immunol Immunother"},{"key":"BFaps201340_CR8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/BF00568199","volume":"16","author":"DW Empey","year":"1979","unstructured":"Empey DW, Laitinen LA, Young GA, Bye CE, Hughes DT . Comparison of the antitussive effects of codeine phosphate 20 mg, dextromethorphan 30 mg and noscapine 30 mg using citric acid-induced cough in normal subjects. Eur J Clin Pharmacol 1979; 16: 393\u20137.","journal-title":"Eur J Clin Pharmacol"},{"key":"BFaps201340_CR9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/BF00315110","volume":"39","author":"MO Karlsson","year":"1990","unstructured":"Karlsson MO, Dahlstrom B, Eckernas SA, Johansson M, Alm AT . Pharmacokinetics of oral noscapine. Eur J Clin Pharmacol 1990; 39: 275\u20139.","journal-title":"Eur J Clin Pharmacol"},{"key":"BFaps201340_CR10","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1083\/jcb.104.3.395","volume":"104","author":"PJ Sammak","year":"1987","unstructured":"Sammak PJ, Gorbsky GJ, Borisy GG . Microtubule dynamics in vivo: a test of mechanisms of turnover. J Cell Biol 1987; 104: 395\u2013405.","journal-title":"J Cell Biol"},{"key":"BFaps201340_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2174\/1568011053352569","volume":"5","author":"J Zhou","year":"2005","unstructured":"Zhou J, Giannakakou P . Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 2005; 5: 65\u201371.","journal-title":"Curr Med Chem Anticancer Agents"},{"key":"BFaps201340_CR12","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1158\/1535-7163.MCT-09-0366","volume":"8","author":"EA Perez","year":"2009","unstructured":"Perez EA . Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther 2009; 8: 2086\u201395.","journal-title":"Mol Cancer Ther"},{"key":"BFaps201340_CR13","first-page":"2584","volume":"56","author":"S Ranganathan","year":"1996","unstructured":"Ranganathan S, Dexter DW, Benetatos CA, Chapman AE, Tew KD, Hudes GR . Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res 1996; 56: 2584\u20139.","journal-title":"Cancer Res"},{"key":"BFaps201340_CR14","doi-asserted-by":"publisher","first-page":"17118","DOI":"10.1074\/jbc.272.27.17118","volume":"272","author":"P Giannakakou","year":"1997","unstructured":"Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997; 272: 17118\u201325.","journal-title":"J Biol Chem"},{"key":"BFaps201340_CR15","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/JCO.1999.17.6.1786","volume":"17","author":"M Monzo","year":"1999","unstructured":"Monzo M, Rosell R, Sanchez JJ, Lee JS, O'Brate A, Gonzalez-Larriba JL, et al. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 1999; 17: 1786\u201393.","journal-title":"J Clin Oncol"},{"key":"BFaps201340_CR16","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1124\/mol.105.021899","volume":"69","author":"R Aneja","year":"2006","unstructured":"Aneja R, Vangapandu SN, Lopus M, Chandra R, Panda D, Joshi HC . Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma. Mol Pharmacol 2006; 69: 1801\u20139.","journal-title":"Mol Pharmacol"},{"key":"BFaps201340_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1023\/A:1020288015457","volume":"60","author":"SV Sheleg","year":"2002","unstructured":"Sheleg SV, Korotkevich EA, Zhavrid EA, Muravskaya GV, Smeyanovich AF, Shanko YG, et al. Local chemotherapy with cisplatin-depot for glioblastoma multiforme. J Neurooncol 2002; 60: 53\u20139.","journal-title":"J Neurooncol"},{"key":"BFaps201340_CR18","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S1357-2725(01)00106-6","volume":"34","author":"K Datta","year":"2002","unstructured":"Datta K, Babbar P, Srivastava T, Sinha S, Chattopadhyay P . p53 dependent apoptosis in glioma cell lines in response to hydrogen peroxide induced oxidative stress. Int J Biochem Cell Biol 2002; 34: 148\u201357.","journal-title":"Int J Biochem Cell Biol"},{"key":"BFaps201340_CR19","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1093\/jnci\/86.20.1517","volume":"86","author":"TC Chou","year":"1994","unstructured":"Chou TC, Motzer RJ, Tong Y, Bosl GJ . Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86: 1517\u201324.","journal-title":"J Natl Cancer Inst"},{"key":"BFaps201340_CR20","first-page":"1121","volume":"28","author":"EW Newcomb","year":"2006","unstructured":"Newcomb EW, Lukyanov Y, Schnee T, Ali MA, Lan L, Zagzag D . Noscapine inhibits hypoxia-mediated HIF-1alpha expression andangiogenesis in vitro: a novel function for an old drug. Int J Oncol 2006; 28: 1121\u201330.","journal-title":"Int J Oncol"},{"key":"BFaps201340_CR21","doi-asserted-by":"publisher","first-page":"92","DOI":"10.2174\/157489209787002524","volume":"4","author":"M Mahmoudian","year":"2009","unstructured":"Mahmoudian M, Rahimi-Moghaddam P . The anti-cancer activity of noscapine: a review. Recent Pat Anticancer Drug Discov 2009; 4: 92\u20137.","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"BFaps201340_CR22","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou TC . Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621\u201381.","journal-title":"Pharmacol Rev"},{"key":"BFaps201340_CR23","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/CAD.0b013e3282ffd68d","volume":"19","author":"EW Newcomb","year":"2008","unstructured":"Newcomb EW, Lukyanov Y, Smirnova I, Schnee T, Zagzag D . Noscapine induces apoptosis in human glioma cells by an apoptosis-inducing factor-dependent pathway. Anticancer Drugs 2008; 19: 553\u201363.","journal-title":"Anticancer Drugs"},{"key":"BFaps201340_CR24","doi-asserted-by":"publisher","first-page":"5038","DOI":"10.1038\/sj.onc.1205593","volume":"21","author":"MA Antonyak","year":"2002","unstructured":"Antonyak MA, Kenyon LC, Godwin AK, James DC, Emlet DR, Okamoto I, et al. Elevated JNK activation contributes to the pathogenesis of human brain tumors. Oncogene 2002; 21: 5038\u201346.","journal-title":"Oncogene"},{"key":"BFaps201340_CR25","doi-asserted-by":"publisher","first-page":"e4545","DOI":"10.1371\/journal.pone.0004545","volume":"4","author":"M Jeong","year":"2009","unstructured":"Jeong M, Kwon YS, Park SH, Kim CY, Jeun SS, Song KW, et al. Possible novel therapy for malignant gliomas with secretable trimeric TRAIL. PloS One 2009; 4: e4545.","journal-title":"PloS One"},{"key":"BFaps201340_CR26","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/sj.bjc.6601193","volume":"89","author":"T Kanzawa","year":"2003","unstructured":"Kanzawa T, Germano IM, Kondo Y, Ito H, Kyo S, Kondo S . Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide. Br J Cancer 2003; 89: 922\u20139.","journal-title":"Br J Cancer"},{"key":"BFaps201340_CR27","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/sj.bjc.6690802","volume":"81","author":"M Brada","year":"1999","unstructured":"Brada M, Judson I, Beale P, Moore S, Reidenberg P, Statkevich P, et al. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 1999; 81: 1022\u201330.","journal-title":"Br J Cancer"},{"key":"BFaps201340_CR28","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/BF00254236","volume":"22","author":"G Chen","year":"1988","unstructured":"Chen G, Pan QC . Potentiation of the antitumor activity of cisplatin in mice by 3-aminobenzamide and nicotinamide. Cancer Chemother Pharmacol 1988; 22: 303\u20137.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFaps201340_CR29","doi-asserted-by":"publisher","first-page":"371","DOI":"10.7326\/0003-4819-144-5-200603070-00015","volume":"144","author":"MR Gilbert","year":"2006","unstructured":"Gilbert MR . New treatments for malignant gliomas: careful evaluation and cautious optimism required. Ann Intern Med 2006; 144: 371\u20133.","journal-title":"Ann Intern Med"},{"key":"BFaps201340_CR30","doi-asserted-by":"publisher","first-page":"9809","DOI":"10.1158\/0008-5472.CAN-07-0625","volume":"67","author":"P Pyrko","year":"2007","unstructured":"Pyrko P, Schonthal AH, Hofman FM, Chen TC, Lee AS . The unfolded protein response regulator GRP78\/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res 2007; 67: 9809\u201316.","journal-title":"Cancer Res"},{"key":"BFaps201340_CR31","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/annonc\/mdi225","volume":"16","author":"M Barrie","year":"2005","unstructured":"Barrie M, Couprie C, Dufour H, Figarella-Branger D, Muracciole X, Hoang-Xuan K, et al. Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. Ann Oncol 2005; 16: 1177\u201384.","journal-title":"Ann Oncol"},{"key":"BFaps201340_CR32","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.surneu.2005.06.024","volume":"65","author":"MA Altinoz","year":"2006","unstructured":"Altinoz MA, Bilir A, Del Maestro RF, Tuna S, Ozcan E, Gedikoglu G . Noscapine and diltiazem augment taxol and radiation-induced S-phase arrest and clonogenic death of C6 glioma in vitro. Surg Neurol 2006; 65: 478\u201384.","journal-title":"Surg Neurol"},{"key":"BFaps201340_CR33","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.canlet.2011.08.015","volume":"312","author":"N Jhaveri","year":"2011","unstructured":"Jhaveri N, Cho H, Torres S, Wang W, Schonthal AH, Petasis NA, et al. Noscapine inhibits tumor growth in TMZ-resistant gliomas. Cancer Lett 2011; 312: 245\u201352.","journal-title":"Cancer Lett"},{"key":"BFaps201340_CR34","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/j.ejca.2010.02.017","volume":"46","author":"R Aneja","year":"2010","unstructured":"Aneja R, Miyagi T, Karna P, Ezell T, Shukla D, Vij Gupta M, et al. A novel microtubule-modulating agent induces mitochondrially driven caspase-dependent apoptosis via mitotic checkpoint activation in human prostate cancer cells. Eur J Cancer 2010; 46: 1668\u201378.","journal-title":"Eur J Cancer"}],"updated-by":[{"DOI":"10.1038\/s41401-021-00762-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000}}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/aps201340.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/aps201340","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/aps201340.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T12:37:24Z","timestamp":1630672644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/aps201340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,27]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["BFaps201340"],"URL":"https:\/\/doi.org\/10.1038\/aps.2013.40","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,27]]},"assertion":[{"value":"25 December 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41401-021-00762-w","URL":"https:\/\/doi.org\/10.1038\/s41401-021-00762-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}